Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3026% above fair value
$538.60−4.02 (-0.74%)
Close on Nov 13, 2026Market cap $136.51BP/E 31.4Yield –
Vertex Pharmaceuticals price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Vertex Pharmaceuticals's price to book ratio was 6.8× on Nov 11, 2026, against 6.4× a year earlier. Over the last 5 years it ranged from 5.4× to 8.7×, with a median of 6.4×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.8× | +0.2 |
| 2025 | Dec 31, 2025 | 6.6× | +0.0 |
| 2024 | Dec 31, 2024 | 6.6× | +0.3 |
| 2023 | Dec 29, 2023 | 6.4× | +0.7 |
| 2022 | Dec 30, 2022 | 5.7× | −0.2 |
| 2021 | Dec 31, 2021 | 5.9× | −1.7 |
| 2020 | Dec 31, 2020 | 7.6× | −3.2 |
| 2019 | Dec 31, 2019 | 10.7× | −3.9 |
| 2018 | Dec 31, 2018 | 14.6× | −6.6 |
| 2017 | Dec 29, 2017 | 21.1× | +3.3 |
| 2016 | Dec 30, 2016 | 17.9× | −15.6 |
| 2015 | Dec 31, 2015 | 33.5× | +8.8 |
| 2014 | Dec 31, 2014 | 24.7× | +11.0 |
| 2013 | Dec 31, 2013 | 13.7× | +4.9 |
| 2012 | Dec 31, 2012 | 8.8× | −3.1 |
| 2011 | Dec 30, 2011 | 11.9× | – |
See a number that looks wrong?